Company profile
ALCON INC
NYSE:ALCOphthalmic Goods
Drug pipeline (53)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acoltremon | approved | — | 0 | — |
| Atropine sulfate | approved | — | 0 | — |
| BETAXOLOL HYDROCHLORIDE | approved | — | 0 | — |
| Brimonidine tartrate | approved | — | 11 | approved |
| BRINZOLAMIDE | approved | — | 14 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (257)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00767481 | phase3 | terminated | 2008-10-01 | 2009-02-01 | Alcon Research | 1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT |
| NCT00643669 | phase2 | completed | 2008-02-01 | 2008-04-01 | Alcon Research | 24 Hour IOP Lowering Efficacy of AL-3789 |
| NCT02770248 | phase4 | completed | 2016-05-23 | 2017-01-14 | Alcon Research | 24-hr Intraocular Pressure Control With SIMBRINZA ® |
| NCT02140060 | phase2 | completed | 2014-06-01 | 2014-11-01 | Alcon Research | 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension |
| NCT00311389 | phase3 | completed | 2003-01-01 | 2004-09-01 | Alcon Research | A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension |
FDA applications (60)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 061645 | ANDA | ALCON LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 061648 | ANDA | ALCON LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 062339 | ANDA | ALCON LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 062523 | ANDA | ALCON PHARMACEUTICALS LTD | ||||
Loading… | ||||||
| ANDA 062628 | ANDA | ALCON LABORATORIES INC | ||||
Loading… | ||||||